-
Share
27,811 Posts.
107
28/01/22
09:41
Share
(COVID & common cold nasal spray)
Nasodine kills SARS-CoV-2 (COVID-19) in vitro
In 2021 - Divisional patent covering SARS-CoV-2 ( COVID-19) allowed in US (expires 2041)
Human pilot study in COVID-positive subjects in South Africa. Nasodine reduced SARS-CoV-2 shedding for up to 1hr in 83% of subjects.
Almost half the investors were doctors or scientists.
It has patented the idea, and has done a Phase 3 clinical trial.
It expected to start the second Phase 3 trial this year funded from the IPO, with the aim of getting regulatory approvals.
The company was founded in 2012, by Dr Peter Molloy, who launched Betadine Sore Throat Gargle in Australia, and Dr Stephen Goodall.
-
